Draw/line
Home / Guides / 06

Approved, compounded or research-only

FDA-approved, compounded and research-use-only peptides: what each status means and what changed in 2026.

5 min read · By the Drawline team · Reviewed

Where a compound sits legally tells you how much oversight stands behind it. In the United States there are three broad situations.

  • FDA-approved drugs have been through clinical trials and are made under manufacturing controls. Semaglutide and tirzepatide are examples.
  • Compounded drugs are prepared by pharmacies for individual patients on a prescription. They are not FDA-approved and are allowed only under specific conditions.
  • “Research use only” products are sold outside both systems, with no assurance of identity, dose or sterility for human use.

What changed recently

FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025, which removed the main basis for large-scale compounding of those drugs. In April 2026 the agency restated limits on compounded copies of approved GLP-1 drugs.

Also in April 2026, FDA said it would remove a group of peptides, including BPC-157 and TB-500, from its list of substances flagged for significant safety risks, and scheduled advisory committee review. Legal analysts stressed that this step alone did not authorize pharmacies to compound them. In July 2026 an FDA advisory committee narrowly recommended six of them, including BPC-157 and TB-500, for the compounding list. That vote is advisory. Nothing changes legally until FDA completes rulemaking, so check FDA’s compounding pages for the current position.

Sources: Polsinelli on peptide compounding; Goodwin on the advisory committee review; Polsinelli on compounded GLP-1 policy; AJMC on the July 2026 vote.

This guide is for research and educational use. It is not medical advice. Confirm anything that affects your health with a licensed professional.